PH12016501079A1 - (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND - Google Patents

(6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND

Info

Publication number
PH12016501079A1
PH12016501079A1 PH12016501079A PH12016501079A PH12016501079A1 PH 12016501079 A1 PH12016501079 A1 PH 12016501079A1 PH 12016501079 A PH12016501079 A PH 12016501079A PH 12016501079 A PH12016501079 A PH 12016501079A PH 12016501079 A1 PH12016501079 A1 PH 12016501079A1
Authority
PH
Philippines
Prior art keywords
methyl
pyrazino
octahydro
azetidine
dioxo
Prior art date
Application number
PH12016501079A
Other languages
English (en)
Inventor
Inoue Satoshi
Yamamoto Yuji
Iso Kentaro
Original Assignee
Prism Pharma Co Ltd
Eisai R And D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prism Pharma Co Ltd, Eisai R And D Man Co Ltd filed Critical Prism Pharma Co Ltd
Publication of PH12016501079A1 publication Critical patent/PH12016501079A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PH12016501079A 2013-12-25 2016-06-07 (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND PH12016501079A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013267687 2013-12-25
PCT/JP2014/083932 WO2015098853A1 (ja) 2013-12-25 2014-12-22 (6S,9aS)-N-ベンジル-6-[(4-ヒドロキシフェニル)メチル]-4,7-ジオキソ-8-({6-[3-(ピペラジン-1-イル)アゼチジン-1-イル]ピリジン-2-イル}メチル)-2-(プロプ-2-エン-1-イル)-オクタヒドロ-1H-ピラジノ[2,1-c][1,2,4]トリアジン-1-カルボキサミド化合物

Publications (1)

Publication Number Publication Date
PH12016501079A1 true PH12016501079A1 (en) 2016-07-11

Family

ID=53399298

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016501079A PH12016501079A1 (en) 2013-12-25 2016-06-07 (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND

Country Status (34)

Country Link
US (1) US9174998B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP3088401B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6085040B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102307053B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN105873932B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR098908A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2014371148B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112016013572B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2932435C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2016001419A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1122521T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK3088401T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2728353T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20190908T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE044541T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL245961A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO3809B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT3088401T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME03391B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX365376B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY173946A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20160932A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12016501079A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL3088401T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT3088401T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS58955B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2669805C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201604496YA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI3088401T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT201900306T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR201908392T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI681961B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA116923C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2015098853A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
SG11201700855XA (en) 2014-08-28 2017-03-30 Eisai R&D Man Co Ltd High-purity quinoline derivative and method for manufacturing same
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR20250020678A (ko) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US11369623B2 (en) * 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
RU2723551C2 (ru) 2015-06-23 2020-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
CN108084067B (zh) * 2016-11-22 2019-08-30 重庆圣华曦药业股份有限公司 一种立他司特中间体的制备方法
AU2018219637B2 (en) 2017-02-08 2023-07-13 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CA3155672A1 (en) 2019-10-29 2021-05-06 Yoichi Ozawa Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
AR121544A1 (es) * 2020-03-12 2022-06-15 3 2 Pharma Inhibidores de la vía de señalización por cbp / catenina y sus usos
EP4238567A4 (en) 2020-10-30 2024-09-04 Keio University NEW TREATMENT AND PREVENTION OF DISEASES RELATED TO SARCOPENIA
US20240352020A1 (en) * 2021-08-26 2024-10-24 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof
CN117794544A (zh) * 2021-09-08 2024-03-29 卫材R&D管理有限公司 实体瘤治疗用医药组合物
CN116262120A (zh) * 2021-12-13 2023-06-16 上海中医药大学 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用
WO2023140369A1 (en) * 2022-01-18 2023-07-27 Prism BioLab Co., Ltd. Phosphoric acid derivatives
KR20240167633A (ko) 2022-03-31 2024-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료용 약학 조성물
CN115784934A (zh) * 2022-11-22 2023-03-14 上海吉奉生物科技有限公司 一种酪氨酸衍生物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310215T3 (es) * 2001-10-12 2009-01-01 Choongwae Pharma Corporation Estructuras mimeticas de giro inverso y metodo relacionado.
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
ES2552239T3 (es) 2008-06-06 2015-11-26 Prism Pharma Co., Ltd. Miméticos de hélice alfa y métodos relacionados con los mismos
SG175045A1 (en) * 2009-04-15 2011-11-28 Jw Pharmaceutical Corp Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
KR101892575B1 (ko) * 2010-10-14 2018-08-31 제이더블유중외제약 주식회사 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
WO2012115286A1 (en) * 2011-02-25 2012-08-30 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto

Also Published As

Publication number Publication date
TWI681961B (zh) 2020-01-11
RS58955B1 (sr) 2019-08-30
JPWO2015098853A1 (ja) 2017-03-23
CN105873932A (zh) 2016-08-17
RU2016122867A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-06-18
ES2728353T3 (es) 2019-10-23
SG11201604496YA (en) 2016-07-28
JO3809B1 (ar) 2021-01-31
HRP20190908T1 (hr) 2019-08-09
BR112016013572A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-10-03
SI3088401T1 (sl) 2019-08-30
CA2932435C (en) 2021-08-17
CN105873932B (zh) 2017-11-24
HK1222656A1 (zh) 2017-07-07
IL245961A0 (en) 2016-08-02
KR20160094980A (ko) 2016-08-10
TW201609736A (zh) 2016-03-16
MY173946A (en) 2020-02-28
PE20160932A1 (es) 2016-09-10
AR098908A1 (es) 2016-06-22
CY1122521T1 (el) 2021-01-27
AU2014371148B2 (en) 2018-08-09
MX2016007705A (es) 2017-01-11
SMT201900306T1 (it) 2019-07-11
EP3088401A4 (en) 2017-06-28
PL3088401T3 (pl) 2019-09-30
JP6085040B2 (ja) 2017-02-22
UA116923C2 (uk) 2018-05-25
PT3088401T (pt) 2019-06-12
MX365376B (es) 2019-05-31
AU2014371148A1 (en) 2016-06-23
NZ720718A (en) 2020-10-30
US20150175615A1 (en) 2015-06-25
WO2015098853A1 (ja) 2015-07-02
BR112016013572B1 (pt) 2023-03-21
RU2669805C2 (ru) 2018-10-16
DK3088401T3 (da) 2019-06-03
EP3088401B1 (en) 2019-03-06
US9174998B2 (en) 2015-11-03
TR201908392T4 (tr) 2019-07-22
HUE044541T2 (hu) 2019-10-28
KR102307053B1 (ko) 2021-10-01
LT3088401T (lt) 2019-07-25
RU2016122867A (ru) 2018-02-01
CA2932435A1 (en) 2015-07-02
ME03391B (me) 2020-01-20
EP3088401A1 (en) 2016-11-02
CL2016001419A1 (es) 2017-01-20

Similar Documents

Publication Publication Date Title
PH12016501079A1 (en) (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
PH12014501719B1 (en) Pyridone derivatives
NZ705705A (en) Ret inhibitor
TN2015000175A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
PH12016502398A1 (en) Dihydropyrimido loop derivative as hbv inhibitor
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
PH12015501813A1 (en) Monocyclic pyridine derivative
IN2015DN01035A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2012DE00621A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014DN07509A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2012DE00620A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX344911B (es) Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
MY185971A (en) Pyranodipyridine compound
MY178583A (en) Hydantoin derivative
MX358151B (es) Derivado de sitaxentan.
MX355654B (es) Derivado de paroxetina.
WO2014125233A3 (fr) Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
MX2014008995A (es) Compuesto novedoso de ester de acido acetico o una sal del mismo.
MX345518B (es) Compuestos analgesicos, metodos, y formulaciones.
MY181470A (en) Novel fluorinated benzilic acid ester compound and salt thereof
JO3123B1 (ar) مشتقات كينولين-تحتوي على مركبات دوائية